Horizon Therapeutics plc
https://www.horizontherapeutics.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Horizon Therapeutics plc
Horizon Makes The Case For An Ambitious $10Bn Sales Goal
The rare disease specialist held its first R&D day since acquiring Viela Bio and laid out the development strategy for four mid-stage drugs to drive long-term growth.
Novartis's Big Hopes For Transplant Drug Blown Apart
Long touted as one of the drugs to watch in the Swiss giant's pipeline, iscalimab's chances of replacing tacrolimus as the standard of care preventing organ rejection in transplant patients have been dealt a hefty blow after a Phase II trial failure.
Genmab To Expand Proprietary Pipeline, Closing In On Marketing Its Own Products
The antibody discovery and development biotech Genmab is preparing to commercialize its own products in the second half of 2021, as revenues continue to grow from partners and licensees.
Horizon Headed For A Breakout Year As Tepezza Relaunch Exceeds Goals
Thyroid eye disease drug Tepezza is now expected to generate more than $1.55bn in full year sales, despite missing a full quarter of revenue.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Bio-Technology General Corporation
- Crealta Holdings LLC
- Crealta Pharmaceuticals
- Curzion Pharmaceuticals, Inc.
- Encode Pharmaceuticals, Inc.
- Horizon Pharma plc
- Hyperion Therapeutics, Inc. (Andromeda Biotech Ltd)
- Nitec Pharma AG
- Raptor Pharmaceutical Corp.
- River Vision Development Corp.
- Savient Pharmaceuticals, Inc. (SVNT)
- TorreyPines Therapeutics, Inc. (Neurogenetics Inc.)
- Vidara Therapeutics Inc
- Viela Bio, Inc.